Results 181 to 190 of about 3,554 (229)

Personalized Medicine in Acromegaly: The ACROFAST Study.

J Clin Endocrinol Metab
Marques-Pamies M, Gil J, Sampedro-Nuñez M, Valassi E, Biagetti B, Giménez-Palop O, Hernández M, Martínez S, Carrato C, Villar-Taibo R, Araujo-Castro M, Blanco C, Simón-Muela I, Simó-Servat A, Xifra G, Vázquez F, Pavón I, Rosado JA, García-Centeno R, Zavala R, Hanzu FA, Mora M, Aulinas A, Vilarrasa N, Librizzi S, Calatayud M, de Miguel P, Alvarez-Escola C, Picó A, Salinas I, Fajardo-Montañana C, Cámara R, Bernabéu I, Jordà M, Webb SM, Marazuela M, Puig-Domingo M.   +36 more
europepmc   +1 more source

Healthcare utilization and costs among patients with acromegaly in the United States. [PDF]

J Comp Eff Res
Quock TP, Chang E, Das AK, Speller A, Tarbox MH, Rossi ML, Rattana SK, Paulson IE, Broder MS.   +8 more
europepmc   +1 more source

Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis. [PDF]

J Endocrinol Invest
Costanza F, Basile C, Chiloiro S, Hessman E, Chantzichristos D, Pontecorvi A, Bobbio E, Fleseriu M, Esposito D.   +8 more
europepmc   +1 more source

GSBS News, Spring 2007 [PDF]

, 2007
Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston/M.D. Anderson Cancer Center
core   +1 more source

Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy. [PDF]

Acta Neurochir (Wien)
Atai S, Wiedmann M, Dahlberg D, Bollerslev J, Heck A.   +4 more
europepmc   +1 more source

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance. [PDF]

Pharmaceuticals (Basel)
Popa Ilie IR, Dobrea CM, Butuca A, Homorodean C, Morgovan C, Vonica-Tincu AL, Gligor FG, Ghibu S, Frum A.   +8 more
europepmc   +1 more source

Predictive factors for post-therapeutic biochemical discordance in acromegaly: a monocentric analysis of 156 cases. [PDF]

Pituitary
Emmanouilidis D, Polanski W, Juratli T, Sobottka SB, Tsourdi E, Gruber M, Pinzer T, Eyüpoglu IY.   +7 more
europepmc   +1 more source

Efficacy and safety of pegvisomant in patients with acromegaly – A real life perspective from a tertiary center

Helena Urbano Ferreira, Inês Meira, João Menino, Juliana Gonçalves, Sandra Belo, Jorge Pedro, Davide Carvalho, Joana Queirós   +7 more
openalex   +1 more source

Prevalence, comorbidities and treatment outcomes of patients with Acromegaly in Qatar. Running title: Acromegaly in Qatar

Elhadd T, Mahmuod EAA, Ponirakis G, Dabbous Z, Rohani Z, Abdalrubb A, Malik RA, Bashir M.   +7 more
europepmc   +1 more source